Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.35 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.35 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.34 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 3/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4655597 | 0.89 | OPRM1 (0.46) | OPRM1LMNADNM1SMPD1TSHR | |
| SCHEMBL20225052 | 0.89 | OPRM1 (0.46) | OPRM1LMNADNM1SMPD1TSHR | |
| SCHEMBL28995100 | 0.89 | OPRM1 (0.46) | OPRM1LMNADNM1SMPD1TSHR | |
| SCHEMBL4557947 | 0.89 | OPRM1 (0.46) | OPRM1LMNADNM1SMPD1TSHR | |
| SCHEMBL4263417 | 0.89 | OPRM1 (0.46) | OPRM1LMNADNM1SMPD1TSHR | |
| SCHEMBL23270390 | 0.89 | OPRM1 (0.46) | OPRM1LMNADNM1SMPD1TSHR | |
| SCHEMBL6554404 | 0.89 | OPRM1 (0.46) | OPRM1LMNADNM1SMPD1TSHR | |
| SCHEMBL10045699 | 0.89 | OPRM1 (0.46) | OPRM1LMNADNM1SMPD1TSHR | |
| SCHEMBL28744275 | 0.89 | OPRM1 (0.46) | OPRM1LMNADNM1SMPD1TSHR | |
| SCHEMBL724923 | 0.89 | OPRM1 (0.46) | OPRM1LMNADNM1SMPD1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10071110-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-09-11 | — | — | US | disclosed |
| US-20170333459-A1 | METHODS OF TREATING ORTHOPOX VIRUS INFECTIONS AND ASSOCIATED DISEASES | CHIMERIX, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170239279-A1 | PHOSPHONATE COMPOUNDS | UNIV CALIFORNIA (US) | 2017-08-24 | — | — | US | disclosed |
| US-9649321-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160067268-A1 | PHOSPHONATE COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-10 | — | — | US | disclosed |
| US-9206208-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150141375-A1 | Methods of Treating Viral Associated Diseases | CHIMERIX, INC. | 2015-05-21 | — | — | US | disclosed |
| EP-2842559-A2 | Compounds, compositions and methods for the treatment of viral infections and other medical disorders | Chimerix, Inc. (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20150051174-A1 | Phosphonate Compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-19 | — | — | US | disclosed |
| US-8889658-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-18 | — | — | US | disclosed |
| US-20070003608-A1 | Compounds, compositions and methods for the treatment of viral infections and other medical disorders | CHIMERIX, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20060281706-A1 | New phosphonate ester derivatives of drugs such as antivirals cidofovir, adefovir, tenofovir, azidothymidine (AZT), or bisphosphonates such as alendronate, or anticancers such as cytosine arabinoside; side effect reduction, less toxic; antiviral | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-12-14 | — | — | US | disclosed |
| US-7098197-B2 | An antiviral nucleoside in which the 5'-hydroxyl group has been substituted for a phosphonate or methyl phosphonate that is covalently linked to an alkylethanediol; osteoporosis; anticarcinogenic agents; viricides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-08-29 | — | — | US | disclosed |
| US-7094772-B2 | guanin-9-yl, adenin-9-yl, 2,6-diaminopurin-9-yl, 2-aminopurin-9-yl or their 1-deaza, 3-deaza, or 8-aza compounds, or cytosin-1-yl - ethoxymethanephosphonic acid derivatives, used to treat osteoporosis and other disorders of bone metabolism, cancer, or viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-08-22 | — | — | US | disclosed |
| US-7034014-B2 | New derivatives of cidofovir, adefovir, cyclic cidofovir or tenofovir made by forming phosphonate ester with an alcohol such as alkylglycerol, alkylpropanediol, 1-S-alkylthioglycerol, alkoxyalkanol or alkylethanediol; e.g. 1-O-octadecylpropanediol-3-cidofovir; side effect reduction, less toxic; antiviral | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-04-25 | — | — | US | disclosed |
| US-20050182019-A1 | An antiviral nucleoside in which the 5'-hydroxyl group has been substituted for a phosphonate or methyl phosphonate that is covalently linked to an alkylethanediol; osteoporosis; anticarcinogenic agents; viricides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-08-18 | — | — | US | disclosed |
| US-20050176673-A1 | guanin-9-yl, adenin-9-yl, 2,6-diaminopurin-9-yl, 2-aminopurin-9-yl or their 1-deaza, 3-deaza, or 8-aza compounds, or cytosin-1-yl - ethoxymethanephosphonic acid derivatives, used to treat osteoporosis and other disorders of bone metabolism, cancer, or viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-08-11 | — | — | US | disclosed |
| US-20040127735-A1 | New phosphonate ester derivatives of drugs such as antivirals cidofovir, adefovir, tenofovir, azidothymidine (AZT), or bisphosphonates such as alendronate, or anticancers such as cytosine arabinoside; side effect reduction, less toxic; antiviral | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-07-01 | — | — | US | disclosed |
| US-6716825-B2 | OSTEOPOROSIS AND OTHER DISORDERS OF BONE METABOLISUM, CANCER, VIRAL INFECTIONS, AND THE LIKE. | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-04-06 | — | — | US | disclosed |
| US-20040019232-A1 | Analogs of phosphonate and bisphosphonate compounds based on bone resorption suppressors (alendronic acid), viricides (cidofovir) and antineoplastic agents (bemcitabine); nontoxic; bioavailability; side effects reduction | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051174-A1 | Phosphonate Compounds | PHPT1, PHOSPHO1, PIK3CA | OPRM1 4237/4885ZDHHC7 2654/4885LMNA 2747/4885 |
| US-20050176673-A1 | guanin-9-yl, adenin-9-yl, 2,6-diaminopurin-9-yl, 2-aminopurin-9-yl or their 1-deaza, 3-deaza, or 8-aza compounds, or cytosin-1-yl - ethoxymethanephosphonic acid derivatives, used to treat osteoporosis and other disorders of bone metabolism, cancer, or viral infections | ENPP1, ADA, ENTPD5 | OPRM1 4565/4885ZDHHC7 3347/4885LMNA 2121/4885 |
| US-10071110-B2 | Phosphonate compounds | PHPT1, PHOSPHO1, PIK3CA | OPRM1 4237/4885ZDHHC7 2654/4885LMNA 2747/4885 |
| US-20060281706-A1 | New phosphonate ester derivatives of drugs such as antivirals cidofovir, adefovir, tenofovir, azidothymidine (AZT), or bisphosphonates such as alendronate, or anticancers such as cytosine arabinoside; side effect reduction, less toxic; antiviral | TYMP, ADA, DCTD | OPRM1 3113/4885ZDHHC7 2245/4885LMNA 3566/4885 |
| US-20040127735-A1 | New phosphonate ester derivatives of drugs such as antivirals cidofovir, adefovir, tenofovir, azidothymidine (AZT), or bisphosphonates such as alendronate, or anticancers such as cytosine arabinoside; side effect reduction, less toxic; antiviral | TYMP, ADA, DCTD | OPRM1 3113/4885ZDHHC7 2245/4885LMNA 3566/4885 |
| US-20040019232-A1 | Analogs of phosphonate and bisphosphonate compounds based on bone resorption suppressors (alendronic acid), viricides (cidofovir) and antineoplastic agents (bemcitabine); nontoxic; bioavailability; side effects reduction | BPGM, PPA1, INPP5D | OPRM1 4036/4885ZDHHC7 3348/4885LMNA 3308/4885 |
| US-20170239279-A1 | PHOSPHONATE COMPOUNDS | PHPT1, PHOSPHO1, PIK3CA | OPRM1 4237/4885ZDHHC7 2654/4885LMNA 2747/4885 |
| US-20160067268-A1 | PHOSPHONATE COMPOUNDS | PHPT1, PHOSPHO1, PIK3CA | OPRM1 4237/4885ZDHHC7 2654/4885LMNA 2747/4885 |
| US-20050182019-A1 | An antiviral nucleoside in which the 5'-hydroxyl group has been substituted for a phosphonate or methyl phosphonate that is covalently linked to an alkylethanediol; osteoporosis; anticarcinogenic agents; viricides | MTAP, SAMHD1, NT5C3B | OPRM1 2574/4885ZDHHC7 680/4885LMNA 1745/4885 |
| US-20170333459-A1 | METHODS OF TREATING ORTHOPOX VIRUS INFECTIONS AND ASSOCIATED DISEASES | OAT, PNPO, OTC | OPRM1 3311/4885ZDHHC7 2771/4885LMNA 4178/4885 |
| US-20070003608-A1 | Compounds, compositions and methods for the treatment of viral infections and other medical disorders | ACE, CYP27A1, LIPC | OPRM1 1401/4885ZDHHC7 489/4885LMNA 2125/4885 |
| US-20150141375-A1 | Methods of Treating Viral Associated Diseases | HAVCR2, EIF2AK2, TSLP | OPRM1 4250/4885ZDHHC7 713/4885LMNA 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.